Stockscreener 앱 받기
1.43
1.42%
0.02
시장 영업 전:
1.48
0.05
+3.50%
전일 마감가:
$1.41
열려 있는:
$1.38
하루 거래량:
20,675
Relative Volume:
0.28
시가총액:
$14.08M
수익:
-
순이익/손실:
$-19.44M
주가수익비율:
-0.5379
EPS:
-2.6585
순현금흐름:
$-12.71M
1주 성능:
-3.38%
1개월 성능:
-16.86%
6개월 성능:
-41.87%
1년 성능:
-67.84%
1일 변동 폭
$1.38
$1.46
1주일 범위
$1.3501
$1.50
52주 변동 폭
$1.17
$5.817
인에잇바이오 Stock (INAB) Company Profile
명칭
In 8 Bio Inc
전화
(646) 600-6438
주소
EMPIRE STATE BUILDING, NEW YORK
Compare INAB vs VRTX, REGN, ARGX, ALNY, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INAB
In 8 Bio Inc
|
1.43 | 14.08M | 0 | -19.44M | -12.71M | -2.6585 |
VRTX
Vertex Pharmaceuticals Inc
|
431.86 | 109.85B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
760.27 | 80.38B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
765.43 | 47.60B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
319.52 | 42.63B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.03 | 35.19B | 606.42M | -1.28B | -997.58M | -6.403 |
인에잇바이오 Stock (INAB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-03-18 | 개시 | Laidlaw | Buy |
| 2022-08-30 | 개시 | H.C. Wainwright | Buy |
인에잇바이오 주식(INAB)의 최신 뉴스
8 Most Oversold Penny Stocks to Buy Right Now - Insider Monkey
Adaptin Bio shares approved for OTCQB quotation under ticker APTN; trading to begin in 6-8 weeks - TradingView
Adaptin Bio (APTN) wins OTCQB quotation and advances APTN-101 program - Stock Titan
ImmunityBio (NASDAQ: IBRX) outlines response to FDA ad concerns - Stock Titan
Climb Bio, Inc. 8-K Filing Details: Company Information, Address, and Stock Exchange Listing (April 2026) - Minichart
Entera Bio (NASDAQ: ENTX) completes private placement with BVF funds - Stock Titan
Climb Bio (CLYM) consolidates CFO and principal accounting officer roles - Stock Titan
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Inc.
Instil Bio (TIL) replaces Deloitte with RSM as independent auditor - Stock Titan
[144] Annovis Bio, Inc. SEC Filing - Stock Titan
Palisade Bio (NASDAQ: PALI) sells 1.54M shares to Iterative Health affiliate - Stock Titan
GOSS SEC FilingsGossamer Bio 10-K, 10-Q, 8-K Forms - Stock Titan
KALA SEC FilingsKala Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
APTN SEC FilingsAdaptin Bio 10-K, 10-Q, 8-K Forms - Stock Titan
Kala Bio (NASDAQ: KALA) notifies SEC of late 2025 10‑K, cites turnover - Stock Titan
LeonaBio (NASDAQ: ATHA) expands Sermonix deal disclosure and ELAINE-3 trial spend - Stock Titan
ImmunityBio (NASDAQ: IBRX) adds $75M non-dilutive cash and converts $25M debt - stocktitan.net
Passage Bio Inc Stock: Gene Therapy Innovator Faces Clinical and Funding Hurdles in Competitive Biot - AD HOC NEWS
Vor Bio (Nasdaq: VOR) secures $75M private placement to fund telitacicept - Stock Titan
[8-K] Instil Bio, Inc. Reports Material Event - Stock Titan
Tela Bio targets at least 8% revenue growth in 2026 while advancing commercial transformation - MSN
LeonaBio (NASDAQ: LONA) boosts cash to fund Phase 3 breast cancer drug - stocktitan.net
Upstream Bio (NASDAQ: UPB) establishes $150M at-the-market stock program - Stock Titan
bioAffinity Technologies (BIAF) shares March 2026 investor presentation materials - Stock Titan
Upstream Bio (NASDAQ: UPB) deepens 2025 loss while推进 Phase 3 verekitug strategy - Stock Titan
Tevogen Bio Holdings Inc. Files Form 8-K on NASDAQ: Company Details and Key Information for March 2026 - Minichart
Annovis Bio, Inc. Files Form 8-K with NYSE Listing and Corporate Information for March 23, 2026 - Minichart
Annovis Bio's Mark Guerin departs as CFO; Maria Maccecchini to serve as Acting CFO - TradingView
CFO departs Annovis Bio (ANVS) as CEO Maria Maccecchini takes acting finance role - Stock Titan
Tevogen Bio (TVGN) restores Nasdaq bid-price compliance after 1-for-50 reverse split - Stock Titan
bioAffinity Technologies (BIAF) plans CyPath Lung webinar showcasing real-world clinical use - Stock Titan
TELA Sees Growth with FY26 Revenue Projected to Rise at Least 8% - GuruFocus
TELA Bio (NASDAQ: TELA) lifts 2025 sales 16% but posts $38.8M loss - Stock Titan
Medical device maker secures up to $70M after 18% sales gain - Stock Titan
INmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on Monday, March 30th. - The Manila Times
INmune Bio will discuss 2025 results and corporate update March 30 - stocktitan.net
PALI SEC FilingsPalisade Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Cabaletta Bio (NASDAQ: CABA) details 2025 results and advances rese-cel trials - Stock Titan
ANVS SEC FilingsAnnovis Bio Inc 10-K, 10-Q, 8-K Forms - stocktitan.net
UPB SEC FilingsUpStream Bio Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Palisade Bio Inc expected to post a loss of 8 cents a shareEarnings Preview - TradingView
TELA Bio Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
TELA Bio (TELA) hit with Nasdaq $1 bid-price deficiency, faces delisting risk - Stock Titan
NUVB SEC FilingsNuvation Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
[8-K] BIO-PATH HOLDINGS, INC. Reports Material Event | BPTH SEC FilingForm 8-K - Stock Titan
LeonaBio (ATHA) wins approval for 2026 equity plan and major share increase - Stock Titan
[EFFECT] Gossamer Bio, Inc. SEC Filing - Stock Titan
Passage BIO (PASG) CEO receives 58,000-share stock option grant - Stock Titan
[144] KALA BIO, Inc. SEC Filing - Stock Titan
Gossamer Bio (NASDAQ: GOSS) 2025 loss widens as seralutinib Phase 3 misses goal - Stock Titan
Phase 3 trial push deepens 2025 loss at Annovis Bio (NYSE: ANVS) - Stock Titan
인에잇바이오 (INAB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.47%
2.75%
자본화:
|
볼륨(24시간):